Arena Pharmaceuticals (ARNA) Stock Price, News & Analysis

Company Overview

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Key Stats

• Today's Range: $99.99 to $99.99
• 50-Day Range: $93.13 to $99.99
• 52-Week Range: $45.50 to $100.00
• Volume: 107 shs
• Average Volume: 1.56 million shs
• Market Capitalization: $6.17 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARNA Stock Analysis - Frequently Asked Questions

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) EPS for the quarter, missing the consensus estimate of ($2.53) by $0.68.

When did Arena Pharmaceuticals' stock split?

Shares of Arena Pharmaceuticals reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Meta Platforms (META), Cytokinetics (CYTK), Micron Technology (MU), Bristol-Myers Squibb (BMY) and Canopy Growth (CGC).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 6/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ARNA
• CIK: 1080709
• Web: www.arenapharm.com
• Phone: (858) 453-7200
• Fax: 858-453-7210
• Employees: 448
• Year Founded: 1977

Profitability

• EPS (Most Recent Fiscal Year): ($10.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$616.43 million
• Net Margins: N/A
• Pretax Margin: -1,141,542.63%
• Return on Equity: -69.83%
• Return on Assets: -62.35%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 8.59
• Quick Ratio: 8.59

Sales & Book Value

• Annual Sales: $50 thousand
• Price / Sales: 123,305.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.94 per share
• Price / Book: 9.14

Miscellaneous

• Outstanding Shares: 61,659,000
• Free Float: 60,173,000
• Market Cap: $6.17 billion
• Optionable: Optionable
• Beta: 0.55